Considering that the targeted clearance of TDP-43, in particular by co-chaperones, is a key strategy for therapeutic intervention in ALS and FTLD55, insights into client specificity by JDPs are decisive to nominate potential disease biomarkers11,58. The gene discussed is TARDBP; the disease is amyotrophic lateral sclerosis.